T Karantanos1,2, S Karanika3, B Seth3, G Gignac4. 1. Medical Oncology Department, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, 401 North Broadway Ave, Baltimore, MD, 21287, USA. Theodoroskarantanosmd@gmail.com. 2. General Internal Medicine Department, Boston Medical Center, Boston University School of Medicine, 850 Harrison Ave, Boston, MA, 02118, USA. Theodoroskarantanosmd@gmail.com. 3. General Internal Medicine Department, Boston Medical Center, Boston University School of Medicine, 850 Harrison Ave, Boston, MA, 02118, USA. 4. Hematology-Oncology, Department of Internal Medicine, Boston Medical Center, Boston University School of Medicine, 820 Harrison Ave, FGH Building, 1st Floor, Boston, MA, 02118, USA.
Abstract
INTRODUCTION: The neutrophil-to-lymphocyte (ANC/ALC) ratio is associated with worse prognosis in patients with NSCLC on immunotherapies, but the role of ALC remains unclear. The previous radiation therapy causes lymphopenia, and given approaches of combining radiation with immunotherapies, it is critical to better understand the impact of peripheral lymphocytes. PATIENTS AND METHODS: We evaluated retrospectively 22 patients with advanced NSCLC treated with nivolumab at Boston Medical Center from January 2014 to September 2016 and correlated the peripheral blood counts with the overall survival (OS) and overall time on treatment. We assessed the effect of the previous radiation on peripheral blood counts and clinical outcomes. RESULTS: Baseline ALC and ANC/ALC ratios are positively and negatively correlated, respectively, with the OS on nivolumab. The ALC and ALC/WBC ratios at 6 weeks on treatment are positively associated with the OS. Kaplan-Meier analysis at baseline and at 6 weeks showed significantly increased OS in the group of patients with the highest ALC. The previous radiation therapy was positively correlated with the ANC and negatively correlated with the ALC/WBC ratio at 8 weeks after the initiation of nivolumab. CONCLUSION: Our finding that ALC at baseline and at 6 weeks on treatment is positively correlated with the OS provides an easily obtained predictive marker. Our result that the previous radiation is associated with higher ANC and lower ALC during treatment supports that the combination of radiation therapy with immunotherapy should be carefully applied and potentially peripheral blood counts can be utilized to stratify patients for this approach.
INTRODUCTION: The neutrophil-to-lymphocyte (ANC/ALC) ratio is associated with worse prognosis in patients with NSCLC on immunotherapies, but the role of ALC remains unclear. The previous radiation therapy causes lymphopenia, and given approaches of combining radiation with immunotherapies, it is critical to better understand the impact of peripheral lymphocytes. PATIENTS AND METHODS: We evaluated retrospectively 22 patients with advanced NSCLC treated with nivolumab at Boston Medical Center from January 2014 to September 2016 and correlated the peripheral blood counts with the overall survival (OS) and overall time on treatment. We assessed the effect of the previous radiation on peripheral blood counts and clinical outcomes. RESULTS: Baseline ALC and ANC/ALC ratios are positively and negatively correlated, respectively, with the OS on nivolumab. The ALC and ALC/WBC ratios at 6 weeks on treatment are positively associated with the OS. Kaplan-Meier analysis at baseline and at 6 weeks showed significantly increased OS in the group of patients with the highest ALC. The previous radiation therapy was positively correlated with the ANC and negatively correlated with the ALC/WBC ratio at 8 weeks after the initiation of nivolumab. CONCLUSION: Our finding that ALC at baseline and at 6 weeks on treatment is positively correlated with the OS provides an easily obtained predictive marker. Our result that the previous radiation is associated with higher ANC and lower ALC during treatment supports that the combination of radiation therapy with immunotherapy should be carefully applied and potentially peripheral blood counts can be utilized to stratify patients for this approach.
Authors: Dirk Tomsitz; Max Schlaak; Sarah Zierold; Giulia Pesch; Thomas U Schulz; Genoveva Müller; Christine Zecha; Lars E French; Lucie Heinzerling Journal: Cancers (Basel) Date: 2022-07-05 Impact factor: 6.575
Authors: Tsz Him So; Sik Kwan Chan; Wing Lok Chan; Horace Choi; Chi Leung Chiang; Victor Lee; Tai Chung Lam; Ian Wong; Simon Law; Dora Kwong; Feng Ming Spring Kong; Jian Yue Jin; Ka On Lam Journal: Adv Radiat Oncol Date: 2020-04-19
Authors: Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal Journal: Front Oncol Date: 2021-04-21 Impact factor: 6.244
Authors: Zarique Z Akanda; Paul J Neeson; Thomas John; Stephen Barnett; Gerard G Hanna; Alistair Miller; Ross Jennens; Shankar Siva Journal: Transl Lung Cancer Res Date: 2021-06
Authors: Soehartati A Gondhowiardjo; Marlinda Adham; Lisnawati Rachmadi; Henry Kodrat; Demak Lumban Tobing; I Made Haryoga; Agustinus Gatot Dwiyono; Yoseph Adi Kristian; Tiara Bunga Mayang Permata Journal: PLoS One Date: 2020-03-19 Impact factor: 3.240